The Activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group

Abstract

The Bone and Soft Tissue Tumor Study Group (BSTTSG) of the Japan Clinical Oncology Group (JCOG) was established in 2002. At present, 26 institutions are participating as active members of the BSTTSG of the JCOG. In 2004, the first BSTTSG trial, JCOG 0304, was initiated. JCOG 0304 was a Phase II study of perioperative chemotherapy with doxorubicin and ifosfamide for patients with operable, high-grade, non-round cell soft tissue sarcomas (T2bN0M0) arising in the extremities. The results of JCOG 0304 suggested the efficacy of the perioperative chemotherapy on operable soft tissue sarcoma in the extremities and led to planning of the subsequent clinical trial for the disease. The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma. The BSTTSG is also conducting a JCOG ancillary study, JCOG 0905-A1, to evaluate the gene expression profiles of osteosarcoma treated in the JCOG 0905 study. The BSTTSG will further try to develop new standard therapy for bone and soft tissue tumors.

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study

“…Consequently, we included 1070 patients (557 in the training set and 513 in the validation set) who had a complete set of data for prognostic variables. Among these patients, the chemotherapy regimen in the Japanese cohort was based on a protocol composed of methotrexate, doxorubicin, and cisplatin (MAP) or MAP plus ifosfamide 20, 21. The majority of the patients in the Korean cohort were treated with MAP 22…”

Dedifferentiated Liposarcoma in the Spermatic Cord Finally Diagnosed at 7th Resection of Recurrence: A Case Report and Bibliographic Consideration

“…With regard to the effectiveness of adjuvant therapy [ 5 , 6 ], the addition of radiotherapy (50–60 Gy) is efficacious in the case of resected margins within 1 cm [ 7 ]. Moreover, pre- and postoperative chemotherapy with Adriamycin, ifosfamide, and eliburin reportedly improves prognosis for grade 2 or 3 sarcomas of more than 5 cm [ 8 ]. Hence, adjuvant chemotherapy and/or radiotherapy should be considered in cases of high risk for recurrence such as dedifferentiated type.…”

Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth

“…We evaluated the effect of anticancer agents including CDDP, IFO, and DOX, which are standard chemotherapeutic reagents for osteosarcoma patients in Japan (18). To determine whether ATO and standard anticancer agents prevent the proliferation of osteosarcoma cells, we performed WST-1 assays using ATO, CDDP, IFO, and DOX.…”